Th1 and Th2 cytokines are elevated in HCV-infected SVR(-) patients treated with interferon-α

Biochemical and Biophysical Research Communications

Volumn 379, Issue 4, 2009, Pages 855-860

  Wan, Lei ^a,b,c   Kung, Yung Jen ^a   Lin, Ying Ju ^b,c   Liao, Chiu Chu ^a   Sheu, Jim J C ^a,b   Tsai, Yuhsin ^b   Lai, Hsueh Chou ^a   Peng, Cheng Yuan ^a   Tsai, Fuu Jen ^a,b,c  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

Author keywords

Cytokines; HCV; Interferon alpha; SVR

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RANTES; RIBAVIRIN; TUMOR NECROSIS FACTOR; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMETRY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TH1 CELL; TH2 CELL; TREATMENT FAILURE; VIRUS INFECTIVITY;

ANTIVIRAL AGENTS; CYTOKINES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; TH1 CELLS; TH2 CELLS; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 58949097368     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.12.114     Document Type: Article

References (32)

1. Seeff L.B., and Hoofnagle J.H. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 36 (2002) S1-S2
2. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5 (2005) 215-229
3. Boyer N., and Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J. Hepatol. 32 (2000) 98-112
4. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., Shiffman M.L., Zeuzem S., Craxi A., Ling M.H., and Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339 (1998) 1493-1499
5. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., and Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339 (1998) 1485-1492
6. Gerotto M., Dal P.F., Sullivan D.G., Chemello L., Cavalletto L., Polyak S.J., Pontisso P., Gretch D.R., and Alberti A. Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alpha. J. Viral Hepat. 6 (1999) 367-372
7. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 14 (2001) 778-809 table
8. Koziel M.J., Dudley D., Wong J.T., Dienstag J., Houghton M., Ralston R., and Walker B.D. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J. Immunol. 149 (1992) 3339-3344
9. Shimizu Y.K., Hijikata M., Iwamoto A., Alter H.J., Purcell R.H., and Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J. Virol. 68 (1994) 1494-1500
10. Cacciarelli T.V., Martinez O.M., Gish R.G., Villanueva J.C., and Krams S.M. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 24 (1996) 6-9
11. Gutterman J.U. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. USA 91 (1994) 1198-1205
12. Parronchi P., De C.M., Manetti R., Simonelli C., Sampognaro S., Piccinni M.P., Macchia D., Maggi E., Del P.G., and Romagnani S. IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J. Immunol. 149 (1992) 2977-2983
13. Abayli B., Canataroglu A., and Akkiz H. Serum profile of T helper 1 and T helper 2 cytokines in patients with chronic hepatitis C virus infection. Turk. J. Gastroenterol. 14 (2003) 7-11
14. el-Kady I.M., el-Masry S.A., Badra G., and Halafawy K.A. Different cytokine patterns in patients coinfected with hepatitis C virus and Schistosoma mansoni. Egypt. J. Immunol. 11 (2004) 23-29
15. Cribier B., Schmitt C., Rey D., Lang J.M., Kirn A., and Stoll-Keller F. Production of cytokines in patients infected by hepatitis C virus. J. Med. Virol. 55 (1998) 89-91
16. Cecere A., Marotta F., Vangieri B., Tancredi L., and Gattoni A. Progressive liver injury in chronic hepatitis C infection is related to altered cellular immune response and to different citokine profile. Panminerva Med. 46 (2004) 171-187
17. Shapiro S., Gershtein V., Elias N., Zuckerman E., Salman N., and Lahat N. mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients: effects of interferon-alpha (IFN-alpha) treatment. Clin. Exp. Immunol. 114 (1998) 55-60
18. Gramenzi A., Andreone P., Loggi E., Foschi F.G., Cursaro C., Margotti M., Biselli M., and Bernardi M. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J. Viral Hepat. 12 (2005) 525-530
19. Polyak S.J., Khabar K.S., Rezeiq M., and Gretch D.R. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J. Virol. 75 (2001) 6209-6211
20. Mahmood S., Sho M., Yasuhara Y., Kawanaka M., Niiyama G., Togawa K., Ito T., Takahashi N., Kinoshita M., and Yamada G. Clinical significance of intrahepatic interleukin-8 in chronic hepatitis C patients. Hepatol. Res. 24 (2002) 413-419
21. Koo B.C., McPoland P., Wagoner J.P., Kane O.J., Lohmann V., and Polyak S.J. Relationships between hepatitis C virus replication and CXCL-8 production in vitro. J. Virol. 80 (2006) 7885-7893
22. Locksley R.M. Interleukin 12 in host defense against microbial pathogens. Proc. Natl. Acad. Sci. USA 90 (1993) 5879-5880
23. Bigger C.B., Guerra B., Brasky K.M., Hubbard G., Beard M.R., Luxon B.A., Lemon S.M., and Lanford R.E. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J. Virol. 78 (2004) 13779-13792
24. Bigger C.B., Brasky K.M., and Lanford R.E. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J. Virol. 75 (2001) 7059-7066
25. Brice G.T., Graber N.L., Hoffman S.L., and Doolan D.L. Expression of the chemokine MIG is a sensitive and predictive marker for antigen-specific, genetically restricted IFN-gamma production and IFN-gamma-secreting cells. J. Immunol. Methods 257 (2001) 55-69
26. Diepolder H.M., Zachoval R., Hoffmann R.M., Wierenga E.A., Santantonio T., Jung M.C., Eichenlaub D., and Pape G.R. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346 (1995) 1006-1007
27. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., Houghton M., Parham P., and Walker C.M. Analysis of a successful immune response against hepatitis C virus. Immunity 10 (1999) 439-449
28. Ferrari C., Urbani S., Penna A., Cavalli A., Valli A., Lamonaca V., Bertoni R., Boni C., Barbieri K., Uggeri J., and Fiaccadori F. Immunopathogenesis of hepatitis C virus infection. J. Hepatol. 31 Suppl 1 (1999) 31-38
29. Bassett S.E., Thomas D.L., Brasky K.M., and Lanford R.E. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J. Virol. 73 (1999) 1118-1126
30. Tsai S.L., Liaw Y.F., Chen M.H., Huang C.Y., and Kuo G.C. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25 (1997) 449-458
31. Bergqvist A., and Rice C.M. Transcriptional activation of the interleukin-2 promoter by hepatitis C virus core protein. J. Virol. 75 (2001) 772-781
32. Rao A. Signaling mechanisms in T cells. Crit. Rev. Immunol. 10 (1991) 495-519